Kintegral Advisory LLC Has $508,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Kintegral Advisory LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 32.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,445 shares of the medical device company's stock after selling 3,649 shares during the period. Kintegral Advisory LLC's holdings in DexCom were worth $508,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Private Trust Co. NA boosted its stake in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. Golden State Wealth Management LLC lifted its stake in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Optiver Holding B.V. bought a new stake in DexCom during the fourth quarter worth $33,000. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Finally, Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Down 1.0%

NASDAQ DXCM traded down $0.85 on Friday, reaching $82.73. The company had a trading volume of 1,841,055 shares, compared to its average volume of 4,413,224. The firm has a market cap of $32.44 billion, a price-to-earnings ratio of 61.74, a P/E/G ratio of 1.77 and a beta of 1.44. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19. The business has a 50 day moving average of $83.26 and a two-hundred day moving average of $79.82. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the company earned $0.32 earnings per share. The business's revenue for the quarter was up 12.5% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the sale, the executive vice president owned 95,102 shares of the company's stock, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,190 shares of company stock valued at $2,281,732. 0.32% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Wall Street Zen cut DexCom from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Mizuho assumed coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price for the company. Finally, Piper Sandler cut their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.